[Increase of serum procalcitonin levels during a neuroleptic malignant syndrome].
When fever occurs in a patient treated with a neuroleptic, the diagnosis of a neuroleptic malignant syndrome is difficult to differentiate to that of an infectious event. Among inflammation biomarkers of inflammation, serum procalcitonin levels increase both quickly and specifically during a bacterial infection. We report the first case of a neuroleptic malignant syndrome associated with a significant increase of serum procalcitonin levels, without concomitant septic syndrome. The neuroleptic malignant syndrome might be a non-infectious clinical situation associated with an increased serum procalcitonin concentration.
Cabot
B
B
Unité gériatrique aiguë, UFR Pierre et Marie Curie, Université Paris 6, France.
Pautas
E
E
Gatey
M
M
Perivier
S
S
Mahieux
F
F
Pinquier
C
C
Hausfater
P
P
D000369:Aged, 80 and over; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001831:Body Temperature; D002097:C-Reactive Protein / Q000378:metabolism; D002116:Calcitonin / Q000097:blood*; D015740:Calcitonin Gene-Related Peptide; D003937:Diagnosis, Differential; D005260:Female; D005440:Fluid Therapy; D006212:Hallucinations / Q000209:etiology; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000209:etiology; D009459:Neuroleptic Malignant Syndrome / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D011498:Protein Precursors / Q000097:blood*; D011618:Psychotic Disorders / Q000209:etiology*; D016896:Treatment Outcome
D018712:Analgesics, Non-Narcotic; D014150:Antipsychotic Agents; C000606589:CALCA protein, human; D011498:Protein Precursors; D002116:Calcitonin; D002097:C-Reactive Protein; D006220:Haloperidol; D015740:Calcitonin Gene-Related Peptide